Take the free GLP-1 qualification quiz at https://go.telehealthfx.com/start — see if you are eligible for semaglutide or tirzepatide, delivered to your door with no hidden membership fees. Learn more at https://telehealthfx.com or explore berberine options at https://go.telehealthfx.com/berberine.

🚨 BREAKING: On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list — a move that would permanently restrict large-scale compounding of GLP-1 weight loss medications by outsourcing facilities. If you are currently using a compounded GLP-1 medication or thinking about starting one, this episode of TelehealthFX Talk is essential listening.

In this episode, we break down exactly what the FDA's proposal means in plain English, what's actually changing, and what your real options are right now. We explain the critical difference between 503A traditional compounding pharmacies and 503B outsourcing facilities, why this distinction matters for your access to weight loss medication, and how to make sure you are working with a legitimate, compliant telehealth platform.

👇 HERE'S WHAT WE COVER 👇

• The FDA's April 30, 2026 proposal — what it actually says and what it means for consumers currently on compounded semaglutide or tirzepatide.

• The timeline that led to this moment — from the 2023-2024 national semaglutide shortage, to the shortage resolution in February 2025, to the FDA warning letters in March 2026, and now this proposed rule.

• 503A vs. 503B compounding explained — traditional patient-specific compounding (still legal for documented clinical needs) vs. large-scale outsourcing (the target of this proposal).

• Safety concerns driving the FDA's decision — documented cases of dosing errors, improper storage and temperature control, and unknown ingredients found in some compounded GLP-1 products.

• Your options going forward — brand-name medications like Wegovy and Zepbound are now more accessible than during the shortage era, manufacturer direct-pay programs have reduced out-of-pocket costs, and compliant telehealth platforms provide legitimate clinical oversight.

• Why TelehealthFX is the gold standard — transparent pricing with no hidden membership fees, 24-hour licensed provider review, 2-day UPS shipping, licensed US compounding pharmacies, 1-on-1 onboarding support, and availability in all 50 states for semaglutide, tirzepatide, NAD+, and sermorelin.

• The public comment period — open through June 29, 2026, giving patients, providers, and industry stakeholders an opportunity to weigh in before the rule is finalized.

🔗 TAKE THE NEXT STEP 🔗

• Start your GLP-1 qualification quiz: https://go.telehealthfx.com/start

• Explore berberine options: https://go.telehealthfx.com/berberine

• Visit TelehealthFX: https://telehealthfx.com

🏢 ABOUT TELEHEALTHFX 🏢

TelehealthFX is the trusted clinical weight loss platform offering GLP-1 medications including semaglutide and tirzepatide, plus NAD+ therapy and sermorelin — all through a fully licensed telehealth program available in all 50 states. No hidden membership fees. Transparent pricing. 24-hour provider review. 2-day UPS shipping. Licensed US pharmacies. Real clinical support from day one.

Subscribe to TelehealthFX Talk for weekly episodes on GLP-1 weight loss, telehealth, and clinical wellness. New episodes every week with expert guidance, research-backed information, and honest analysis of the latest FDA regulations and industry changes.

#GLP1 #WeightLoss #Semaglutide #Tirzepatide #OzempicAlternative #TelehealthWeightLoss #TelehealthFX #CompoundedSemaglutide #WeightLossMedication #FDACompounding #503B #ClinicalWeightLoss #WeightManagement #GLP1ForWeightLoss #WeightLossDelivered #Wegovy #Zepbound #Liraglutide #OnlineWeightLoss #NoHiddenFees #GLP1Medications #WeightLossForWomen #WeightLossForSeniors #FDARegulation #CompoundedMedications #Berberine #NADTherapy #Sermorelin #PCOSWeightLoss #InsulinResistance #FatBurning